Thread by @MichalLaurent11

With 2020 almost over, it's time again to look back at some of the BEST in the #bone field: 🔝20 papers (+extras).

Happy to hear your input! Disclosure: fully subjective ranking!
@ASBMR @AcademyEcts @Osteoporosis_NL @osteoporosisNI @mmse30 @NatalieASims

#1 Atypical Femoral fractures @NEJM (Black DM et al.)
Risk reduces within months of @Bisphosphonate1 discontinuation. Benefit>risk in any group but less so in Asians and women <65yr
nejm.org/doi/10.1056/NE…

-side note- @ECTS_science very useful systematic review and recommendations for managing osteoporosis following AFFs.
ncbi.nlm.nih.gov/pmc/articles/P…

And oral BPs may not only reduce fractures but also cardiovascular events
pubmed.ncbi.nlm.nih.gov/32717068/
@Dr_BoAbrahamsen @prieto_alhambra

#2 Individual patient meta-regression confirms Treatment-related changes in #BMD as a surrogate #biomarker for #fracture risk reduction (Black, @md1re & FNIH Bone Quality Project @TheLancetEndo)
Reid comments: No more need for fracture trials? 😜
thelancet.com/journals/landi…

#3 Pooled analysis of #denosumab trials shows small reduction in #falls risk, particularly <75 years of age, justifying further trials of bone drugs with extraskeletal primary outcomes
@mccloskey_e
asbmr.onlinelibrary.wiley.com/doi/full/10.10…

#4 Delayed denosumab injections however surprisingly common in real-world evidence, and associated with less fracture protection, lower BMD gains (DH Solomon, Leder BZ et al.)
pubmed.ncbi.nlm.nih.gov/31894244/

acpjournals.org/doi/10.7326/M2…

#5 @elena_tsourdi @Stu_Ralston & more @EndoSocJournals :
#Systematicreview and updated @ECTS_science position statement on denosumab discontinuation: great overview on a still hot and controversial topic

pubmed.ncbi.nlm.nih.gov/33103722/

#6 Of course we cannot ignore #Covid_19 this year:
@mccloskey_e @ProfNickHarvey et al. report sharp impact on fracture risk assessment @iofbonehealth

link.springer.com/article/10.100…

#7 Six (!) RCTs in JBMR BMD improvements with physical exercise 💪 (@daly_prof @BelindaRBeck Villareal, Schoene, Butler & Fonseca)
pubmed.ncbi.nlm.nih.gov/31797417/
pubmed.ncbi.nlm.nih.gov/32270891/
pubmed.ncbi.nlm.nih.gov/32154945/
pubmed.ncbi.nlm.nih.gov/33295063/
asbmr.onlinelibrary.wiley.com/doi/abs/10.100…

#8 STURDY trial @AnnalsofIM shows 1000 IU #vitaminD best to reduce falls but higher doses may increase falls risk, confirming prior evidence

acpjournals.org/doi/10.7326/M2…

#9 Denosumab with or without cinacalcet for primary hyperparathyroidism (DENOCINA trial, Vestergaard @TheLancetEndo)
Dmab improved BMD but cinacalcet required to control calcemia; dmab further increased PTH...
(too bad no cinacalcet-only group)
thelancet.com/journals/landi…

#10 Evenepoel et al. European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D
Also for bone health in pediatric CKD: pubmed.ncbi.nlm.nih.gov/33245331/
@NephroLeuven @JavaidKassim @prieto_alhambra
pubmed.ncbi.nlm.nih.gov/33098421/

#11 @etiennecavalier within- and between-subject biological variation estimates of BTMs
Important for clinical interpretation especially for #FGF23
...also prize for the longest paper title of 2020 🤪
link.springer.com/article/10.100…

#12 #Teriparatide Did Not Increase Adult #Osteosarcoma Incidence in a 15‐Year US #Postmarketing Surveillance Study
... enough power for final reassurance
asbmr.onlinelibrary.wiley.com/doi/10.1002/jb…

#13 Pharmacological Management of #Osteoporosis in #Postmenopausal Women: An @TheEndoSociety Guideline Update (@md1re @AngelaMCheung & others)

For us, the Belgian Bone Club guidelines were certainly a highlight! @olibruyere
maturitas.org/article/S0378-…

pubmed.ncbi.nlm.nih.gov/32068863/

#14 Determinants of Bone Material Strength and Cortical Porosity in Patients with #Type2Diabetes Mellitus
@TheEndoSociety @skhosla78 @sfeirjad

pubmed.ncbi.nlm.nih.gov/32556277/

What about preclinical papers? (sorry to put clinical earlier😉)
#1 Lipid availability determines fate of skeletal progenitor cells via SOX9
Only bone paper this year @nature
@nickvangastel @SteveStegen @GeertLab @AcademyEcts
#metabolism
nature.com/articles/s4158…

#2 Ablation of #Adipocytes in Adult Mice Induces Massive Bone Gain (Teitelbaum group)
Important for bone-fat interactions and for @BMATscientists @BMA_Society like @VeldhuisVlug
cell.com/cell-metabolis…

#3 ATRAID regulates the action of nitrogen-containing bisphosphonates on bone @LSurfactant @ScienceTM
Atraid-deficient mice had weaker bones and did not respond to N-BP treatment; patients with variants in ATRAID taking N-BPs presented with AFFs and ONJ
stm.sciencemag.org/content/12/544…

#4 Regulation of #FGF23: glycerol-3-phosphate => FGF23 production through G-3-P acyltransferase–mediated lysophosphatidic acid synthesis and LPA receptor 1 @jclinicalinvest

Also, FGF23 linked to anemia in MDS @Martina_MR7
insight.jci.org/articles/view/…

jci.org/articles/view/…

#5 The mechanoresponse of bone is closely related to the #osteocyte lacunocanalicular network architecture @PNASNews @afvantol
...important evidence for osteocytes and the canalicular flow vs. strain hypothesis @LilianIPlotkin

pnas.org/content/early/…

#6 Muscle-derived #interleukin 6 increases exercise capacity by signaling in osteoblasts via RANKL and osteocalcin (Karsenty @jclinicalinvest)
Evidence for local hormonal #muscle-bone interactions important for #exercise
jci.org/articles/view/…

That's it folks!!! Let me know which ones I have to add to the list! #osteoporosis #fractures

@CiviRobyAc